Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer

Kwang Yul Cha, Hyung Min Chung, Dong Ryul Lee, Hwang Kwon, Mi Kyung Chung, Lee Suk Park, Dong Hee Choi, Tae Ki Yoon, Kwang Yul Cha, Hyung Min Chung, Dong Ryul Lee, Hwang Kwon, Mi Kyung Chung, Lee Suk Park, Dong Hee Choi, Tae Ki Yoon

Abstract

Objective: To assess the obstetric outcome of pregnancies resulting from in vitro maturation (IVM) and IVF-ET of immature oocytes retrieved from women with polycystic ovary syndrome (PCOS).

Design: Prospective observational study.

Setting: University fertility clinic.

Patient(s): One hundred thirty-nine women undergoing 203 IVM treatment cycles.

Intervention(s): Immature oocyte recovery from unstimulated ovaries. In vitro oocyte maturation and fertilization. Fresh ET and assessment of obstetric outcomes in the pregnant women.

Main outcome measure(s): Pregnancy and obstetric outcome.

Result(s): Forty-one pregnancies were obtained in 187 ETs, resulting in a pregnancy rate of 21.9%. Except for three patients lost to follow-up in these pregnancies, the abortion and live birth rates were 36.8% (14 of 38) and 63.2% (24 of 38), respectively. The mean (+/-SD) gestational age and birth weight at delivery for singletons were 38.4 +/- 2.0 weeks (range, 33-41.6 weeks) and 3,252 +/- 516 g (1,750-4,100 g), respectively. For twins these were 36.7 +/- 1.9 weeks (34.6-39 weeks) and 2,361 +/- 304 g (1,900-2,990 g), respectively. Pregnancy complications occurred in five patients (13.2%); these included preterm labor (n = 3) and placenta previa (n = 2). Two patients (5.3%) had a major congenital anomaly diagnosed by ultrasonography.

Conclusion(s): The abortion rate, gestational age and birth weight at delivery, and obstetric complications of pregnancies conceived by IVM-ET in women with PCOS were comparable with those of other women with PCOS being treated by conventional IVF-ET. In vitro maturation followed by IVF-ET seems to be a useful treatment option for women with PCOS, thus avoiding the risk of ovarian hyperstimulation syndrome.

Source: PubMed

3
Sottoscrivi